U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C8H15N7O2S3
Molecular Weight 337.445
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FAMOTIDINE

SMILES

NC(=N)NC1=NC(CSCCC(=N)NS(N)(=O)=O)=CS1

InChI

InChIKey=XUFQPHANEAPEMJ-UHFFFAOYSA-N
InChI=1S/C8H15N7O2S3/c9-6(15-20(12,16)17)1-2-18-3-5-4-19-8(13-5)14-7(10)11/h4H,1-3H2,(H2,9,15)(H2,12,16,17)(H4,10,11,13,14)

HIDE SMILES / InChI
Molecular Formula C8H15N7O2S3
Molecular Weight 337.445
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/famotidine.html

Famotidine, a competitive histamine H2-receptor antagonist, is used to treat gastrointestinal disorders such as gastric or duodenal ulcer, gastroesophageal reflux disease, and pathological hypersecretory conditions. Famotidine inhibits many of the isoenzymes of the hepatic CYP450 enzyme system. Other actions of Famotidine include an increase in gastric bacterial flora such as nitrate-reducing organisms. Famotidine binds competitively to H2-receptors located on the basolateral membrane of the parietal cell, blocking histamine affects. This competitive inhibition results in reduced basal and nocturnal gastric acid secretion and a reduction in gastric volume, acidity, and amount of gastric acid released in response to stimuli including food, caffeine, insulin, betazole, or pentagastrin.

CNS Activity

CNS Penetrant
2523
Curator's Comment: Famotidine is a potent highly selective H2 receptor antagonist which crosses the blood-brain barrier.

Originator

Approval Year

1986
104
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2760
 0.3 µM [IC50]
Inhibitor
8228
 6.7 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Approved
8360
PEPCID

Approved Use

PEPCID is indicated in: 1. Short-term treatment of active duodenal ulcer. 2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. 3. Short-term treatment of active benign gastric ulcer. 4. Short-term treatment of gastroesophageal reflux disease (GERD). PEPCID is indicated for shortterm treatment of patients with symptoms of GERD PEPCID is also indicated for the short-term treatment of esophagitis due to GERD including erosive or ulcerative disease diagnosed by endoscopy 5. Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple endocrine adenomas)

Launch Date

5.29632002E11
Curative
Approved
8360
PEPCID

Approved Use

PEPCID is indicated in: 1. Short-term treatment of active duodenal ulcer. 2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. 3. Short-term treatment of active benign gastric ulcer. 4. Short-term treatment of gastroesophageal reflux disease (GERD). PEPCID is indicated for shortterm treatment of patients with symptoms of GERD PEPCID is also indicated for the short-term treatment of esophagitis due to GERD including erosive or ulcerative disease diagnosed by endoscopy 5. Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple endocrine adenomas)

Launch Date

5.29632002E11
Primary
Approved
8360
PEPCID

Approved Use

PEPCID is indicated in: 1. Short-term treatment of active duodenal ulcer. 2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. 3. Short-term treatment of active benign gastric ulcer. 4. Short-term treatment of gastroesophageal reflux disease (GERD). PEPCID is indicated for shortterm treatment of patients with symptoms of GERD PEPCID is also indicated for the short-term treatment of esophagitis due to GERD including erosive or ulcerative disease diagnosed by endoscopy 5. Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple endocrine adenomas)

Launch Date

5.29632002E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
73 ng/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019462s039lbl.pdf
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FAMOTIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
424 ng × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019462s039lbl.pdf
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FAMOTIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019462s039lbl.pdf
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FAMOTIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
82.5%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019462s039lbl.pdf
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FAMOTIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
0.5 mg/kg 2 times / day steady, oral
Recommended
Dose: 0.5 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 0.5 mg/kg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7846741/
unhealthy, 11 - 15 years
n = 8
Health Status: unhealthy
Condition: gastric or duodenal ulcers
Age Group: 11 - 15 years
Sex: M
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/7846741/
Sources:
https://pubmed.ncbi.nlm.nih.gov/7846741/
80 mg 3 times / day steady, oral
Highest studied dose
Dose: 80 mg, 3 times / day
Route: oral
Route: steady
Dose: 80 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/32499303/
unhealthy, 20 - 70 years
n = 10
Health Status: unhealthy
Condition: COVID-19
Age Group: 20 - 70 years
Sex: M+F
Population Size: 10
Sources:
https://pubmed.ncbi.nlm.nih.gov/32499303/
Other AEs: Dizziness, Dry skin...
Other AEs:
Dizziness (grade 1, 2 patients)
Dry skin (grade 1, 1 patient)
Insomnia (grade 1, 1 patient)
Gastrointestinal disorder (NOS) (grade 1, 1 patient)
Forgetfulness (grade 1, 1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/32499303/
1 mg/kg 1 times / day steady, intravenous
Recommended
Dose: 1 mg/kg, 1 times / day
Route: intravenous
Route: steady
Dose: 1 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7846741/
unhealthy, 6 - 15 years
n = 6
Health Status: unhealthy
Condition: gastric or duodenal ulcers
Age Group: 6 - 15 years
Sex: M
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/7846741/
Sources:
https://pubmed.ncbi.nlm.nih.gov/7846741/
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Co-administed with::
ibuprofen(800 mg)
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
n = 1022
Health Status: unhealthy
Condition: chronic pain and inflammation of stomach
Age Group: adult
Sex: M+F
Population Size: 1022
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Other AEs: Anemia, Nausea...
Other AEs:
Anemia (2 patients)
Nausea (6 patients)
Dyspepsia (5 patients)
Diarrhea (5 patients)
Constipation (4 patients)
Abdominal pain upper (3 patients)
Gastroesophageal reflux disease (2 patients)
Vomiting (2 patients)
Stomach discomfort (2 patients)
Abdominal pain (2 patients)
Edema peripheral (2 patients)
Arthralgia (1 patient)
Back pain (2 patients)
Headache (3 patients)
Hypertension (3 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
AEs

AEs

AESignificanceDosePopulation
Dry skin grade 1, 1 patient
80 mg 3 times / day steady, oral
Highest studied dose
Dose: 80 mg, 3 times / day
Route: oral
Route: steady
Dose: 80 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/32499303/
unhealthy, 20 - 70 years
n = 10
Health Status: unhealthy
Condition: COVID-19
Age Group: 20 - 70 years
Sex: M+F
Population Size: 10
Sources:
https://pubmed.ncbi.nlm.nih.gov/32499303/
Forgetfulness grade 1, 1 patient
80 mg 3 times / day steady, oral
Highest studied dose
Dose: 80 mg, 3 times / day
Route: oral
Route: steady
Dose: 80 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/32499303/
unhealthy, 20 - 70 years
n = 10
Health Status: unhealthy
Condition: COVID-19
Age Group: 20 - 70 years
Sex: M+F
Population Size: 10
Sources:
https://pubmed.ncbi.nlm.nih.gov/32499303/
Gastrointestinal disorder (NOS) grade 1, 1 patient
80 mg 3 times / day steady, oral
Highest studied dose
Dose: 80 mg, 3 times / day
Route: oral
Route: steady
Dose: 80 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/32499303/
unhealthy, 20 - 70 years
n = 10
Health Status: unhealthy
Condition: COVID-19
Age Group: 20 - 70 years
Sex: M+F
Population Size: 10
Sources:
https://pubmed.ncbi.nlm.nih.gov/32499303/
Insomnia grade 1, 1 patient
80 mg 3 times / day steady, oral
Highest studied dose
Dose: 80 mg, 3 times / day
Route: oral
Route: steady
Dose: 80 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/32499303/
unhealthy, 20 - 70 years
n = 10
Health Status: unhealthy
Condition: COVID-19
Age Group: 20 - 70 years
Sex: M+F
Population Size: 10
Sources:
https://pubmed.ncbi.nlm.nih.gov/32499303/
Dizziness grade 1, 2 patients
80 mg 3 times / day steady, oral
Highest studied dose
Dose: 80 mg, 3 times / day
Route: oral
Route: steady
Dose: 80 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/32499303/
unhealthy, 20 - 70 years
n = 10
Health Status: unhealthy
Condition: COVID-19
Age Group: 20 - 70 years
Sex: M+F
Population Size: 10
Sources:
https://pubmed.ncbi.nlm.nih.gov/32499303/
Arthralgia 1 patient
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Co-administed with::
ibuprofen(800 mg)
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
n = 1022
Health Status: unhealthy
Condition: chronic pain and inflammation of stomach
Age Group: adult
Sex: M+F
Population Size: 1022
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Abdominal pain 2 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Co-administed with::
ibuprofen(800 mg)
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
n = 1022
Health Status: unhealthy
Condition: chronic pain and inflammation of stomach
Age Group: adult
Sex: M+F
Population Size: 1022
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Anemia 2 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Co-administed with::
ibuprofen(800 mg)
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
n = 1022
Health Status: unhealthy
Condition: chronic pain and inflammation of stomach
Age Group: adult
Sex: M+F
Population Size: 1022
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Back pain 2 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Co-administed with::
ibuprofen(800 mg)
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
n = 1022
Health Status: unhealthy
Condition: chronic pain and inflammation of stomach
Age Group: adult
Sex: M+F
Population Size: 1022
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Edema peripheral 2 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Co-administed with::
ibuprofen(800 mg)
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
n = 1022
Health Status: unhealthy
Condition: chronic pain and inflammation of stomach
Age Group: adult
Sex: M+F
Population Size: 1022
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Gastroesophageal reflux disease 2 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Co-administed with::
ibuprofen(800 mg)
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
n = 1022
Health Status: unhealthy
Condition: chronic pain and inflammation of stomach
Age Group: adult
Sex: M+F
Population Size: 1022
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Stomach discomfort 2 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Co-administed with::
ibuprofen(800 mg)
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
n = 1022
Health Status: unhealthy
Condition: chronic pain and inflammation of stomach
Age Group: adult
Sex: M+F
Population Size: 1022
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Vomiting 2 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Co-administed with::
ibuprofen(800 mg)
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
n = 1022
Health Status: unhealthy
Condition: chronic pain and inflammation of stomach
Age Group: adult
Sex: M+F
Population Size: 1022
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Abdominal pain upper 3 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Co-administed with::
ibuprofen(800 mg)
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
n = 1022
Health Status: unhealthy
Condition: chronic pain and inflammation of stomach
Age Group: adult
Sex: M+F
Population Size: 1022
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Headache 3 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Co-administed with::
ibuprofen(800 mg)
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
n = 1022
Health Status: unhealthy
Condition: chronic pain and inflammation of stomach
Age Group: adult
Sex: M+F
Population Size: 1022
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Hypertension 3 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Co-administed with::
ibuprofen(800 mg)
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
n = 1022
Health Status: unhealthy
Condition: chronic pain and inflammation of stomach
Age Group: adult
Sex: M+F
Population Size: 1022
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Constipation 4 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Co-administed with::
ibuprofen(800 mg)
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
n = 1022
Health Status: unhealthy
Condition: chronic pain and inflammation of stomach
Age Group: adult
Sex: M+F
Population Size: 1022
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Diarrhea 5 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Co-administed with::
ibuprofen(800 mg)
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
n = 1022
Health Status: unhealthy
Condition: chronic pain and inflammation of stomach
Age Group: adult
Sex: M+F
Population Size: 1022
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Dyspepsia 5 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Co-administed with::
ibuprofen(800 mg)
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
n = 1022
Health Status: unhealthy
Condition: chronic pain and inflammation of stomach
Age Group: adult
Sex: M+F
Population Size: 1022
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Nausea 6 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Co-administed with::
ibuprofen(800 mg)
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
n = 1022
Health Status: unhealthy
Condition: chronic pain and inflammation of stomach
Age Group: adult
Sex: M+F
Population Size: 1022
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
1579
inhibitor
1599

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
1509

CYP2B6
799

CYP2C19
1463

OCT1
506

OCT2
638

OCT3
149

MATE1
304

MATE2
261
OCT2
348
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
1673
 weak
likely (co-administration study)
Comment: may lead to substantial increases in blood concentrations of tizanidine, a CYP1A2 substrate; can't find inhibition value
Page: 6.0
OCT2
639
 yes [IC50 114 uM]
OCT1
523
 yes [IC50 28 uM]
OCT3
149
 yes [IC50 6.7 uM]
CYP2B6
985
 yes [Inhibition 100 uM]
CYP2C19
1537
 yes [Inhibition 100 uM]
CYP3A4
1909
 yes [Inhibition 100 uM]
MATE1
306
 yes [Ki 0.6 uM]
MATE2
261
 yes [Ki 9.7 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
OCT2
348
 yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1632
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:4975
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:4975
ChemicalBook
CB5706585
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB5706585
MolPort
MolPort-002-557-620
https://www.molport.com/shop/molecule-link/MolPort-002-557-620
MolPort
MolPort-003-666-342
https://www.molport.com/shop/molecule-link/MolPort-003-666-342
MolPort
MolPort-003-941-395
https://www.molport.com/shop/molecule-link/MolPort-003-941-395
MolPort
MolPort-006-069-255
https://www.molport.com/shop/molecule-link/MolPort-006-069-255
Selleck Chemicals
famotidine-pepcid
http://www.selleckchem.com/products/famotidine-pepcid.html
ZINC
ZINC000001530636
http://zinc15.docking.org/substances/ZINC000001530636
eMolecules
538460
https://www.emolecules.com/cgi-bin/more?vid=538460
eMolecules
6842898
https://www.emolecules.com/cgi-bin/more?vid=6842898
eMolecules
901873
https://www.emolecules.com/cgi-bin/more?vid=901873
PubMed

PubMed

TitleDatePubMed
The effect of rabeprazole alone or in combination with H2 receptor blocker on intragastric pH: a pilot study.
2004 Dec
Switching of H(2)-Receptor Antagonists to Over-the-Counter Status in Finland : Implications for Consumption and Adverse Effects.
2005
[Gastroprotective effects of histamine H2-receptor blockers in Helicobacter-like gastric mucosa lesions].
2005
Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotypes.
2005 Apr
Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3).
2005 Dec
Effect of pre-operative short course famotidine on tumor infiltrating lymphocytes in colorectal cancer: a double blind, placebo controlled, prospective randomized study.
2005 Dec
Synergistic action of famotidine and chlorpheniramine on acetic acid-induced chronic gastric ulcer in rats.
2005 Dec 7
Comparative study of the speed of acid-suppressing effects of oral administration of cimetidine and famotidine.
2005 Jul
Effect of concomitant dosing of famotidine with lansoprazole on gastric acid secretion in relation to CYP2C19 genotype status.
2005 Jul 1
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005 Jun
A prospective randomized trial of either famotidine or omeprazole for the prevention of bleeding after endoscopic mucosal resection and the healing of endoscopic mucosal resection-induced ulceration.
2005 Jun
Comparison of hemostatic effects by route of H2 receptor antagonist administration following endoscopic mucosal resection in patients with neoplastic gastric lesions.
2005 Jun
Preventive therapy for non-steroidal anti-inflammatory drug-induced ulcers in Japanese patients with rheumatoid arthritis: the current situation and a prospective controlled-study of the preventive effects of lansoprazole or famotidine.
2005 Jun
New strategy of therapy for functional dyspepsia using famotidine, mosapride and amitriptyline.
2005 Jun
Usefulness of famotidine in functional dyspepsia patient treatment: comparison among prokinetic, acid suppression and antianxiety therapies.
2005 Jun
Randomized, double-blind, placebo-controlled crossover trial of famotidine in patients with functional dyspepsia.
2005 Jun
Alteration of intracellular histamine H2 receptor cycling precedes antagonist-induced upregulation.
2005 Nov
A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters.
2005 Oct
Effect of preoperative short course famotidine on TILs and survival in breast cancer.
2005 Oct-Dec
Histamine mediates the stimulatory action of ghrelin on acid secretion in rat stomach.
2006 Aug
Assessing the efficacy of famotidine and rebamipide in the treatment of gastric mucosal lesions in patients receiving long-term NSAID therapy (FORCE--famotidine or rebamipide in comparison by endoscopy).
2006 Dec
Attenuation of acid induced oesophagitis in VR-1 deficient mice.
2006 Jan
Coagulation-dependent gene expression and liver injury in rats given lipopolysaccharide with ranitidine but not with famotidine.
2006 May
Tolerance to H2 receptor antagonist correlates well with the decline in efficacy against gastroesophageal reflux in patients with gastroesophageal reflux disease.
2006 Oct
Expression of HSP72 in the gastric mucosa is regulated by gastric acid in rats-correlation of HSP72 expression with mucosal protection.
2006 Oct 20
Omeprazole may be superior to famotidine in the management of iatrogenic ulcer after endoscopic mucosal resection: a prospective randomized controlled trial.
2006 Sep 1
[Clinical study on effect of Jianwei Yuyang Granule in treating patients with gastric ulcer].
2007 Jul
Novel role of famotidine in downregulation of matrix metalloproteinase-9 during protection of ethanol-induced acute gastric ulcer.
2007 Jul 15
The role of tumor necrosis factor alpha in lipopolysaccharide/ranitidine-induced inflammatory liver injury.
2007 Nov
A randomized, double-blind, placebo-controlled clinical study of the histamine H2-receptor antagonist famotidine in Japanese patients with nonerosive reflux disease.
2008
Can negative cardiac effect of proton pump inhibitor and high-dose H2-blocker have clinical influence on patients with stable angina?
2008 Aug
Antinociception induced by central administration of histamine in the formalin test in rats.
2008 Jul-Sep
High-dose intensity pulse interleukin-2 with famotidine has activity in metastatic melanoma.
2008 Oct
[Efficacy and safety of famotidine for the treatment of stress ulcers in neonates].
2008 Oct
Gastroprotective and anti-oxidative properties of ascorbic acid on indomethacin-induced gastric injuries in rats.
2008 Winter
Risk factors for the development of gastric mucosal lesions in rheumatoid arthritis patients receiving long-term nonsteroidal anti-inflammatory drug therapy and the efficacy of famotidine obtained from the FORCE study.
2009
Comparison of the effects of omeprazole and famotidine in treatment of upper abdominal symptoms in patients with reflux esophagitis.
2009
High-dose intensity pulse interleukin-2 with famotidine in metastatic kidney cancer.
2009 Apr
Phosphodiesterase isozymes involved in regulating acid secretion in the isolated mouse stomach.
2009 Dec
Activity of continuous infusion + pulse interleukin-2 with famotidine in metastatic melanoma.
2009 Feb
Comparative study on the gastroprotective potential of some antidepressants in indomethacin-induced ulcer in rats.
2009 Jul 15
Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS).
2009 Jun
Characterization of mechanisms underlying the effects of esomeprazole on the impairment of gastric ulcer healing with addition of NSAID treatment.
2009 Jun
Effects of pantoprazole on ulcer healing delay associated with NSAID treatment.
2009 Mar
[Neurological complications of acute intermittent porphyria precipitated by porphyrinogenic drugs and efficiency of heme-arginate treatment].
2009 Sep
Pulse infusion interleukin-2 with famotidine and cyclophosphamide has activity in previously treated metastatic melanoma.
2010 Apr
Rebamipide may be comparable to H2 receptor antagonist in healing iatrogenic gastric ulcers created by endoscopic mucosal resection: a prospective randomized pilot study.
2010 Apr
Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions.
2010 Jan
Effect of histamine H2 receptor antagonism on levodopa-induced dyskinesia in the MPTP-macaque model of Parkinson's disease.
2010 Jul 30
Hepatoprotective, antinociceptive and antioxidant activities of cimetidine, ranitidine and famotidine as histamine H2 receptor antagonists.
2011 Feb
Patents

Patents

05021582
2
JP2000197427A
2
JP2000219625A
2
JP2000302679A
2
JP2001302510A
2
JP2002017866A
2
JP2002087958A
2
JP2002145776A
2
JP2002291901A
2
JP2002322057A
2
JP2002511777A
412
JP2002537317A
95
JP2002538104A
9
JP2003088495A
2
JP2003095946A
2
JP2003206229A
2
JP2003212772A
2
JP2003261449A
2
JP2003275318A
2
JP2003275324A
2
JP2003275325A
2
JP2003284722A
2
JP2003305122A
2
JP2003515553A
3
JP2004223027A
2
JP2004261566A
2
JP2005168980A
2
JP2006089393A
2
JP2006273819A
2
JP2007008845A
5
JP2007055905A
2
JP2007284453A
2
JP2007507425A
12
JP2007518689A
11
JP2007525670A
147
JP2008504040A
2
JP2009526755A
442
JP2010088502A
2
JP2011079841A
5
JP2011223965A
2
JP2011229496A
2
JP2011525178A
24
JP2011528275A
453
JP4664289B2
2
JP4722295B2
102
JP4732696B2
66
JP4739217B2
51
JP4756823B2
22
JP4763957B2
85
JP4787165B2
100
JPH01100162A
2
JPH01197439A
2

Sample Use Guides

In Vivo Use Guide
The recommended adult oral dosage for active duodenal ulcer is 40 mg once a day at bedtime. Most patients heal within 4 weeks.
Route of Administration: Oral
In Vitro Use Guide
Famotidine (10-1,000 µM) inhibited methadone and oxycodone cytochrome P450-dependent metabolism >50%.
Substance Class Chemical
Created
by admin
on Wed Jul 05 23:21:05 UTC 2023
Edited
by admin
on Wed Jul 05 23:21:05 UTC 2023
Record UNII
5QZO15J2Z8
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FAMOTIDINE
EP   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
FLUXID
Brand Name English
FAMOTIDINE COMPONENT OF PEPCID COMPLETE
Common Name English
GASTER
Brand Name English
MUCLOX
Brand Name English
AMFAMOX
Brand Name English
FAMOXAL
Brand Name English
PEPDUL
Brand Name English
Famotidine [WHO-DD]
Common Name English
[1-Amino-3-[[[2-[(diaminomethylene)amino]-4-thiazolyl]methyl]thio]propylidene]sulfamide
Systematic Name English
FAMOTIDINE [MART.]
Common Name English
PEPCIDINE
Brand Name English
FAMOTIDINE [JAN]
Common Name English
LECEDIL
Brand Name English
MOTIAX
Brand Name English
L 643341
Code English
GANOR
Brand Name English
FAMOTIDINE [MI]
Common Name English
famotidine [INN]
Common Name English
PEPCID COMPLETE COMPONENT FAMOTIDINE
Common Name English
GASTRIDIN
Brand Name English
FAMODIL
Brand Name English
FAMOTIDINE [VANDF]
Common Name English
FAMOTIDINE [USP MONOGRAPH]
Common Name English
YM-11170
Code English
GASTROPEN
Brand Name English
PROPANIMIDAMIDE, N'-(AMINOSULFONYL)-3-(((2-((DIAMINOMETHYLENE)AMINO)-4-THIAZOLYL)METHYL)THIO)-
Systematic Name English
FAMOTIDINE [USP IMPURITY]
Common Name English
FAMOTIDINE [HSDB]
Common Name English
PEPCIDAC
Brand Name English
PEPDINE
Brand Name English
FADUL
Brand Name English
FAMOTIDINE [USP-RS]
Common Name English
FAMOTIDINE [USAN]
Common Name English
FAMOTIDINE [ORANGE BOOK]
Common Name English
FAMOSAN
Brand Name English
PEPCID
Brand Name English
FAMOTIDINE [EP MONOGRAPH]
Common Name English
NSC-757810
Code English
MK-208
Code English
3-((((2-(DIAMINOMETHYLENE)AMINO)-4-THIAZOLYL)METHYL)THIO)-N-SULFAMOYLPROPIONAMIDINE
Common Name English
Classification Tree Code System Code
WHO-ATC A02BA03
Created by admin on Wed Jul 05 23:21:05 UTC 2023 , Edited by admin on Wed Jul 05 23:21:05 UTC 2023
NDF-RT N0000175784
Created by admin on Wed Jul 05 23:21:06 UTC 2023 , Edited by admin on Wed Jul 05 23:21:06 UTC 2023
WHO-VATC QA02BA03
Created by admin on Wed Jul 05 23:21:06 UTC 2023 , Edited by admin on Wed Jul 05 23:21:06 UTC 2023
NCI_THESAURUS C29702
Created by admin on Wed Jul 05 23:21:06 UTC 2023 , Edited by admin on Wed Jul 05 23:21:06 UTC 2023
WHO-ATC A02BA53
Created by admin on Wed Jul 05 23:21:05 UTC 2023 , Edited by admin on Wed Jul 05 23:21:05 UTC 2023
LIVERTOX NBK548228
Created by admin on Wed Jul 05 23:21:05 UTC 2023 , Edited by admin on Wed Jul 05 23:21:05 UTC 2023
WHO-VATC QA02BA53
Created by admin on Wed Jul 05 23:21:06 UTC 2023 , Edited by admin on Wed Jul 05 23:21:06 UTC 2023
NDF-RT N0000000151
Created by admin on Wed Jul 05 23:21:06 UTC 2023 , Edited by admin on Wed Jul 05 23:21:06 UTC 2023
Code System Code Type Description
LACTMED
Famotidine
Created by admin on Wed Jul 05 23:21:05 UTC 2023 , Edited by admin on Wed Jul 05 23:21:05 UTC 2023
PRIMARY
EPA CompTox
DTXSID5023039
Created by admin on Wed Jul 05 23:21:05 UTC 2023 , Edited by admin on Wed Jul 05 23:21:05 UTC 2023
PRIMARY
DRUG BANK
DB00927
Created by admin on Wed Jul 05 23:21:05 UTC 2023 , Edited by admin on Wed Jul 05 23:21:05 UTC 2023
PRIMARY
NSC
757810
Created by admin on Wed Jul 05 23:21:06 UTC 2023 , Edited by admin on Wed Jul 05 23:21:06 UTC 2023
PRIMARY
MESH
D015738
Created by admin on Wed Jul 05 23:21:05 UTC 2023 , Edited by admin on Wed Jul 05 23:21:05 UTC 2023
PRIMARY
EVMPD
SUB07503MIG
Created by admin on Wed Jul 05 23:21:05 UTC 2023 , Edited by admin on Wed Jul 05 23:21:05 UTC 2023
PRIMARY
DAILYMED
5QZO15J2Z8
Created by admin on Wed Jul 05 23:21:05 UTC 2023 , Edited by admin on Wed Jul 05 23:21:05 UTC 2023
PRIMARY
INN
5217
Created by admin on Wed Jul 05 23:21:05 UTC 2023 , Edited by admin on Wed Jul 05 23:21:05 UTC 2023
PRIMARY
SMS_ID
100000092363
Created by admin on Wed Jul 05 23:21:06 UTC 2023 , Edited by admin on Wed Jul 05 23:21:06 UTC 2023
PRIMARY
IUPHAR
7074
Created by admin on Wed Jul 05 23:21:05 UTC 2023 , Edited by admin on Wed Jul 05 23:21:05 UTC 2023
PRIMARY
PUBCHEM
3325
Created by admin on Wed Jul 05 23:21:06 UTC 2023 , Edited by admin on Wed Jul 05 23:21:06 UTC 2023
PRIMARY
MERCK INDEX
M5241
Created by admin on Wed Jul 05 23:21:05 UTC 2023 , Edited by admin on Wed Jul 05 23:21:05 UTC 2023
PRIMARY Merck Index
ChEMBL
CHEMBL902
Created by admin on Wed Jul 05 23:21:05 UTC 2023 , Edited by admin on Wed Jul 05 23:21:05 UTC 2023
PRIMARY
RXCUI
4278
Created by admin on Wed Jul 05 23:21:06 UTC 2023 , Edited by admin on Wed Jul 05 23:21:06 UTC 2023
PRIMARY RxNorm
WIKIPEDIA
FAMOTIDINE
Created by admin on Wed Jul 05 23:21:06 UTC 2023 , Edited by admin on Wed Jul 05 23:21:06 UTC 2023
PRIMARY
RS_ITEM_NUM
1269200
Created by admin on Wed Jul 05 23:21:06 UTC 2023 , Edited by admin on Wed Jul 05 23:21:06 UTC 2023
PRIMARY
CHEBI
4975
Created by admin on Wed Jul 05 23:21:05 UTC 2023 , Edited by admin on Wed Jul 05 23:21:05 UTC 2023
PRIMARY
DRUG CENTRAL
1129
Created by admin on Wed Jul 05 23:21:05 UTC 2023 , Edited by admin on Wed Jul 05 23:21:05 UTC 2023
PRIMARY
USAN
W-33
Created by admin on Wed Jul 05 23:21:06 UTC 2023 , Edited by admin on Wed Jul 05 23:21:06 UTC 2023
PRIMARY
HSDB
3572
Created by admin on Wed Jul 05 23:21:05 UTC 2023 , Edited by admin on Wed Jul 05 23:21:05 UTC 2023
PRIMARY
NCI_THESAURUS
C29045
Created by admin on Wed Jul 05 23:21:05 UTC 2023 , Edited by admin on Wed Jul 05 23:21:05 UTC 2023
PRIMARY
FDA UNII
5QZO15J2Z8
Created by admin on Wed Jul 05 23:21:05 UTC 2023 , Edited by admin on Wed Jul 05 23:21:05 UTC 2023
PRIMARY
CAS
76824-35-6
Created by admin on Wed Jul 05 23:21:05 UTC 2023 , Edited by admin on Wed Jul 05 23:21:05 UTC 2023
PRIMARY
Related Record Type Details
MULTIDRUG AND TOXIN EXTRUSION PROTEIN 1
TRANSPORTER -> INHIBITOR
Structure of FAMOTIDINE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
USP
OAT-1
TRANSPORTER -> INHIBITOR
IC50
Structure of FAMOTIDINE
EXCRETED UNCHANGED
Following IV administration
URINE
HISTAMINE H2 RECEPTOR
TARGET->INVERSE AGONIST
The mean minimum daily requirement of famotidine to control gastric acid hypersecretion was 0.24 g (range 0.08–0.48 g) compared with 2.1 g (range 0.6–3.6 g) for ranitidine and 7.8 g (range 1.2–13.2 g) for cimetidine. is nine times more potent than ranitidine and 32 times more potent than cimetidine, has a longer duration of action than ranitidine or cimetidine,
OCT-2
TRANSPORTER -> INHIBITOR
IC50
OCT-1
TRANSPORTER -> SUBSTRATE
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
HISTAMINE H2 RECEPTOR
TARGET->INVERSE AGONIST
OCT-3
TRANSPORTER -> INHIBITOR
MATE-2
TRANSPORTER -> INHIBITOR
OAT-3
TRANSPORTER -> NON-INHIBITOR
IC50
Structure of FAMOTIDINE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
OCT-1
TRANSPORTER -> INHIBITOR
Related Record Type Details
Structure of FAMOTIDINE SULFOXIDE
METABOLITE -> PARENT
URINE
Related Record Type Details
Structure of FAMOTIDINE CYANOAMIDINE
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 1.4
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 3-((2-(DIAMINOMETHYLENEAMINO)THIAZOL-4-YL)METHYLTHIO)PROPANIMIDAMIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of FAMOTIDINE PROPANAMIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of FAMOTIDINE PROPIONIC ACID
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of FAMOTIDINE PROPANAMIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of FAMOTIDINE DIMER
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 2.5
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of FAMOTIDINE SULFAMOYL PROPANAMIDE
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 1.9
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of FAMOTIDINE DIMER
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of FAMOTIDINE DISULFIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of FAMOTIDINE SULFAMOYL PROPANAMIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of FAMOTIDINE CYANOAMIDINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of FAMOTIDINE PROPIONIC ACID
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 1.7
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 3-((2-(DIAMINOMETHYLENEAMINO)THIAZOL-4-YL)METHYLTHIO)PROPANIMIDAMIDE
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 0.19
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Structure of FAMOTIDINE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966